Endo Investors

Cecelia Health, Inc. is a technology-enabled company based in New York that specializes in remote telehealth support and chronic disease management, particularly focusing on diabetes care. Founded in 2006 and formerly known as Fit4D, the company provides clinical support and coaching services for individuals with Type 1 and Type 2 diabetes, as well as those managing other chronic conditions such as obesity and cardiovascular disease. Cecelia Health combines expert clinical coaching with digital health tools to enhance patient adherence to medications and wellness programs. The company's approach emphasizes personalized coaching and patient engagement, utilizing both virtual care and telehealth solutions to improve health outcomes. Through its services, Cecelia Health aims to transform the lives of its patients by fostering better self-management and promoting positive behavior changes.

Capillary Biomedical, Inc. is a medical device company founded in 2014 and located in Irvine, California. The company focuses on developing innovative technologies for diabetes management, particularly in simplifying glucose monitoring and insulin delivery. As a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University, Capillary Biomedical is dedicated to reducing the burden of diabetes on patients and the healthcare system. Its flagship product features a kink-proof, flexible, multiport cannula designed for reliable and comfortable insulin delivery, with an emphasis on a straightforward one-handed insertion process. This user-friendly design aims to assist diabetes patients in achieving better blood glucose control.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Mellitus Health, Inc. is a healthcare technology company based in Los Angeles, California, that specializes in cloud-based insulin titration software. The company has developed Insulin Insights, an application designed to provide clinicians with precision insulin dosage recommendations. This tool allows for patient-specific dosage adjustments, enabling healthcare providers to optimize insulin regimens effectively. By facilitating more accurate insulin management, Mellitus Health aims to reduce blood glucose levels, minimize complications, and ultimately lower healthcare costs associated with diabetes treatment. Founded in 2013, the company focuses on improving the quality of care for patients requiring insulin therapy.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

ILiAD Biotechnologies, LLC is a clinical-stage biotechnology company established in 2012 and based in Weston, Florida. The company focuses on developing and manufacturing vaccines for diseases caused by Bordetella pertussis, specifically targeting whooping cough. Its lead product, BPZE1, is a live-attenuated pertussis vaccine that has successfully undergone Phase 1 human clinical trials. This vaccine aims to stimulate the immune system to produce protective antibodies, helping patients recover from pertussis and other related illnesses. Through its innovative approach, ILiAD Biotechnologies seeks to contribute to public health by providing effective prevention and treatment options for pertussis-related diseases.